Multiple System Atrophy (MSA)
Clinical guidelines for managing atypical parkinsonian syndromes, evaluating oligodendrocytic α-synuclein GCIs and the hot cross bun sign, and reviewing Midodrine and Fludrocortisone.
Table of Contents
🧠 Standard of Care & Symptoms
Multiple System Atrophy (MSA) is a progressive, adult-onset neurodegenerative disease characterized by severe autonomic failure combined with parkinsonism or cerebellar ataxia.
- Presentation: Autonomic failure plus motor impairments.
- Autonomic Dysfunction: Severe and mandatory for diagnosis. Presents as severe **orthostatic hypotension** (a drop of ≥ 30 mmHg systolic or ≥ 15 mmHg diastolic within 3 minutes of standing), leading to lightheadedness or syncope. Also characterized by neurogenic urinary retention, incontinence, constipation, and erectile dysfunction.
- MSA-P Subtype (Parkinsonian): Parkinsonism is the predominant motor feature, characterized by bradykinesia, rigidity, and postural instability. Unlike Parkinson's Disease, symptoms are typically symmetric and tremor is atypical.
- MSA-C Subtype (Cerebellar): Cerebellar ataxia is the predominant feature, manifesting as progressive gait instability, wide-based gait, limb incoordination (intention tremor, dysmetria), and cerebellar speech (scanning dysarthria).
- Additional Signs: Dysarthria, dysphagia, inspiratory stridor (a high-pitched gasping sound during sleep due to vocal cord paresis), and REM sleep behavior disorder.
🧬 Diagnostics & Oligodendrocytic Glial Inclusions
Diagnosis is based on EAN/MDS criteria, combining clinical autonomic testing, detailed motor exams, and brain MRI scans.
- Brain MRI: Key diagnostic signs.
- Hot Cross Bun Sign: Classic T2-weighted axial MRI finding in the pons, showing a cruciform (cross-like) hyperintensity. This is caused by selective degeneration of pontocerebellar fibers and pontine raphe with sparing of the corticospinal tracts.
- Putaminal Slit-like Hyperintensity: T2-weighted MRI shows a hyperintense rim along the lateral margin of the putamen, accompanied by putaminal atrophy and hypointensity.
- Autonomic Function Tests: Tilt-table testing documenting failure of compensatory heart rate acceleration despite severe blood pressure drops (indicating sympathetic dysregulation).
Pathogenesis & α-Synuclein Glial Cytoplasmic Inclusions (GCIs)
The neurodegeneration in MSA is driven by the pathological aggregation of α-synuclein within glial support cells:
- Oligodendrocytic Target: Unlike Parkinson's Disease and Dementia with Lewy Bodies, where α-synuclein aggregates inside neurons (Lewy bodies), MSA is characterized by the accumulation of hyperphosphorylated **α-synuclein** inside **oligodendrocytes** (the myelin-producing cells of the central nervous system).
- Glial Cytoplasmic Inclusions (GCIs): These aggregates form **glial cytoplasmic inclusions (GCIs)** (also called Papp-Lantos bodies). GCIs disrupt oligodendrocytic support of axons, leading to myelin breakdown, oligodendrocyte apoptosis, and secondary neurodegeneration in the striatonigral (striatum/substantia nigra) and olivopontocerebellar (pons/cerebellum/olives) pathways.
💊 Autonomic Management & Levodopa Non-Responsiveness
There are no disease-modifying therapies. Management focuses on treating orthostatic hypotension, urinary dysfunction, and managing parkinsonian rigidity.
Pharmacological Management of Orthostatic Hypotension
- Midodrine: An alpha-1 adrenergic agonist that induces peripheral vasoconstriction to raise standing blood pressure.
- Fludrocortisone: A mineralocorticoid that promotes renal sodium retention to expand intravascular blood volume.
- Physical Measures: Increasing dietary salt and fluid intake, sleeping with the head of the bed elevated (to reduce nocturnal Hypertension), and wearing high-compression abdominal binders or stockings.
Motor and Urinary Symptom Management
- Levodopa Response: A standard trial of Carbidopa-Levodopa is initiated. Only about 30% of patients show a mild, transient response, which is lost as post-synaptic striatal receptors degenerate.
- Urinary Symptoms: Managed with peripherally acting anticholinergics or clean intermittent self-catheterization for high post-void residuals.
🔬 Active Clinical Trials
Clinical trials are currently evaluating anti-alpha-synuclein antibodies designed to clear extracellular aggregates, myeloperoxidase (MPO) inhibitors to reduce neuroinflammation, and advanced orthostatic hypotensive drugs.
A Phase II study investigating whether infusing an antibody designed to block cell-to-cell propagation of misfolded alpha-synuclein slows the progression of MSA-P.
Key Inclusion: Age 40 to 75, diagnosed with probable or possible MSA, disease duration ≤ 4 years from motor onset, and able to walk with or without assistance.Testing whether inhibiting the MPO enzyme reduces oxidative stress and microglial-mediated neuroinflammation surrounding GCI-containing oligodendrocytes.
Key Inclusion: Age ≥ 40, active diagnosis of probable MSA-P or MSA-C, and baseline orthostatic hypotension drop ≥ 20 mmHg systolic.Evaluating the efficacy of ampreloxetine, a norepinephrine reuptake inhibitor, in preventing syncope and severe orthostatic symptoms in neurogenic orthostatic hypotension.
Key Inclusion: Age ≥ 30, diagnosed with MSA, Parkinson's, or Pure Autonomic Failure, exhibiting a systolic blood pressure drop ≥ 30 mmHg upon standing.🗺️ Next Steps After Diagnosis
If you or a loved one have recently been diagnosed with MSA, coordinate these care pathways:
- Perform Brain MRI: Document the presence of the pontine "hot cross bun sign" or putaminal slit-like hyperintensity to help differentiate MSA from Parkinson's disease.
- Measure Standing Blood Pressures: Perform daily, structured checks (lying down for 5 minutes, then standing at 1 and 3 minutes) to monitor for orthostatic hypotension.
- Consult Autonomic Specialists: Seek out a neurologist specializing in autonomic disorders and a urologist to establish bladder management.
- Optimize Physical Support: Obtain compression stockings and discuss starting Midodrine or Fludrocortisone to manage fainting/lightheadedness.
❓ Patient FAQ
Q: Why does my blood pressure drop so severely when I stand up?
A: In a healthy person, standing up causes gravity to pull blood down into the legs. The brain immediately detects this and signals the autonomic nervous system to constrict blood vessels and increase heart rate to pump blood back up to the brain. In Multiple System Atrophy (MSA), the disease damages the autonomic control centers in the brain and spinal cord. The body fails to constrict blood vessels when standing, causing blood to pool in the lower body, resulting in a sudden drop in blood pressure (orthostatic hypotension) and lightheadedness or fainting.
Q: What is the "hot cross bun sign" on MRI?
A: The "hot cross bun sign" is a distinctive hyperintense (bright white) pattern on T2-weighted brain MRI that resembles a cruciform or cross shape in the pons (part of the brainstem). This shape forms because the disease selectively damages the horizontal pontocerebellar fibers and vertical raphe fibers (leaving a cross-like scar), while sparing the surrounding motor pathways. It is a highly specific marker that strongly supports a diagnosis of Multiple System Atrophy (specifically the cerebellar subtype, MSA-C).
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.